ONTOLOGY SOURCE REFERENCE
Term Source Name	"CHEBI"	"BTO"	"EFO"	"NCBITAXON"	"XCO"	"DOID"	"UBERON"	
Term Source File	"http://data.bioontology.org/ontologies/CHEBI"	"http://data.bioontology.org/ontologies/BTO"	"http://data.bioontology.org/ontologies/EFO"	"http://data.bioontology.org/ontologies/NCBITAXON"	"http://data.bioontology.org/ontologies/XCO"	"http://data.bioontology.org/ontologies/DOID"	"http://data.bioontology.org/ontologies/UBERON"	
Term Source Version	"78"	"20"	"111"	"2"	"33"	"399"	"191"	
Term Source Description	"Chemical Entities of Biological Interest Ontology"	"BRENDA Tissue and Enzyme Source Ontology"	"Experimental Factor Ontology"	"National Center for Biotechnology Information (NCBI) Organismal Classification"	"Experimental Conditions Ontology"	"Human Disease Ontology"	"Uber Anatomy Ontology"	
INVESTIGATION
Investigation Identifier	""
Investigation Title	""
Investigation Description	""
Investigation Submission Date	""
Investigation Public Release Date	""
Comment [Created with configuration]	""
Comment [Last Opened With Configuration]	""
Comment[Created With Configuration]	""
Comment[Last Opened With Configuration]	""
INVESTIGATION PUBLICATIONS
Investigation PubMed ID	""
Investigation Publication DOI	""
Investigation Publication Author List	""
Investigation Publication Title	""
Investigation Publication Status	""
Investigation Publication Status Term Accession Number	""
Investigation Publication Status Term Source REF	""
INVESTIGATION CONTACTS
Investigation Person Last Name	""
Investigation Person First Name	""
Investigation Person Mid Initials	""
Investigation Person Email	""
Investigation Person Phone	""
Investigation Person Fax	""
Investigation Person Address	""
Investigation Person Affiliation	""
Investigation Person Roles	""
Investigation Person Roles Term Accession Number	""
Investigation Person Roles Term Source REF	""
STUDY
Study Identifier	"E-GEOD-16797"
Study Title	"Transcription profiling of Kawasaki disease patients treated with aspirin and IV immunoglobulins. Some patients were also treated with methylprednisone. [original title: Transcription profiling of Kawasaki disease patients who may benefit from methylprednisolone]"
Study Description	"All patients received 30 mg/kg aspirin per day during the acute stage of illness and 5 mg/kg per day after defervescence. Patients were divided into 2 groups. Group B (11 patients) was predicted to be resistant (Egami score ≥ 3) to IV immunoglobulins (IVIG); Group A consisted of 6 randomly-selected patients with Egami scores ≤ 2 and thus predicted to be IVIG-responsive. Among Group B, 6 patients received IVIG treatment, and 5 also received IV methylprednisone. [original description: Clinical score and transcript abundance patterns identify Kawasaki disease patients who may benefit from addition of methylprednisolone. Intravenous immunoglobulin (IVIG) treatment-resistant patients are high risk of developing coronary artery lesions (CALs) with Kawasaki disease (KD). The IVIG-responsive (Group A; n = 6) and -resistant patients (Group B) were predicted before starting the initial treatment using the Egami scoring system, and randomly allocated a single-IVIG treatment group (Group B1; n = 6) or a IVIG-plus-methylprednisolone (IVMP) combined therapy group (Group B2; n = 5). We investigated transcript abundance in the leukocytes of those patients using microarray analysis. Results: five patients in Group A and 1 patient in Group B1 responded to initial IVIG treatment. All Group B2 patients responded to IVIP-plus-IVMP combined therapy. Prior to performing these treatments, those transcripts related to IVIG-resistance and to the development of CALs, such as IL1R, IL18R, oncostatin M, suppressor of cytokine signaling-3, S100A12 protein, carcinoembryonic antigen-related cell adhesion molecule-1, matrix metallopeptidase-9 and polycythemia rubra vera-1 were more abundant in Group B patients in comparison to Group A patients. Moreover, those transcripts in Group B2 patients were more profoundly and broadly suppressed than Group B1 patients after treatment. Conclusion: this study elucidated the molecular mechanism of the effectiveness of IVIG-plus-IVMP combined therapy. 34 samples of pre- and post-treatment in three groups consisting of predicted as IVIG-responsive patients, given single-IVIG treatment patients and IVIG-plus-IVMP combined therapy group in predicted as IVIG-resistant patients. Samples were analyzed without replicates.]"
Comment[Study Grant Number]	""
Comment[Study Funding Agency]	""
Study Submission Date	""
Study Public Release Date	"2010-07-08"
Study File Name	"s_E-GEOD-16797_study_samples.txt"
STUDY DESIGN DESCRIPTORS
Study Design Type	"transcription profiling by array"
Study Design Type Term Accession Number	""
Study Design Type Term Source REF	""
STUDY PUBLICATIONS
Study PubMed ID	"19680167"
Study Publication DOI	"10.1203/PDR.0b013e3181baa3c2"
Study Publication Author List	"Ogata S, Ogihara Y, Nomoto K, Akiyama K, Nakahata Y, Sato K, Minoura K, Kokubo K, Kobayashi H, Ishii M."
Study Publication Title	"Clinical score and transcript abundance patterns identify Kawasaki disease patients who may benefit from addition of methylprednisolone."
Study Publication Status	"published"
Study Publication Status Term Accession Number	"http://www.ebi.ac.uk/efo/EFO_0001796"
Study Publication Status Term Source REF	"EFO"
STUDY FACTORS
Study Factor Name	"phenotype"	"clinical treatment"	"NSAID treatment"	"IVIG treatment"	"IVMP treatment"
Study Factor Type	"phenotype"	"clinical_treatment"	"treatment"	"treatment"	"treatment"
Study Factor Type Term Accession Number	""	""	""	""	""
Study Factor Type Term Source REF	""	""	""	""	""
STUDY ASSAYS
Study Assay File Name	"a_E-GEOD-16797_GeneChip_assay.txt"
Study Assay Measurement Type	"transcription profiling"
Study Assay Measurement Type Term Accession Number	""
Study Assay Measurement Type Term Source REF	""
Study Assay Technology Type	"DNA microarray"
Study Assay Technology Type Term Accession Number	""
Study Assay Technology Type Term Source REF	""
Study Assay Technology Platform	""
STUDY PROTOCOLS
Study Protocol Name	"P-GSE16797-3"	"P-GSE16797-2"	"P-GSE16797-4"	"P-GSE16797-5"	"P-GSE16797-6"	"P-GSE16797-7"	"P-GSE16797-8"	"P-GSE16797-1"
Study Protocol Type	"specified_biomaterial_action"	"specified_biomaterial_action"	"nucleic_acid_extraction"	"labeling"	"hybridization"	"image_aquisition"	"feature_extraction"	"bioassay_data_transformation"
Study Protocol Type Term Accession Number	""	""	""	""	""	""	""	""
Study Protocol Type Term Source REF	""	""	""	""	""	""	""	""
Study Protocol Description	"Groups A (Kd_GA) and B1(KD_GB1) patients were administered single-IVIG treatment (2.0 g/kg for 1 day). Group B2 (KD_GB2) patients received IVMP therapy, 30 mg/kg over 2 hours before receiving IVIG treatment (2.0 g/kg for 1 day). All patients received aspirin (30 mg /kg per day) during the acute stage of illness. The dose of aspirin decreased to 5 mg/kg per day after defervescence."	"The six patients who were predicted IVIG-responders by Egami score were randomly selected Group A (KD_GA). Eleven IVIG-resistant patients predicted by Egami score were randomly assigned to the single-IVIG treatment group (Group KD_GB1; n = 6) and IVIG-plus-IVMP combined therapy group (Group KD_GB2; n = 5)"	"Total RNA was isolated from 2.5 ml of whole blood using a PAXgene tube, according to the manufacturer’s recommended protocol (Paxgene Blood RNA Kit, PreanalytiX, QIAGEN, Valencia, CA). Next alpha-globin and beta-globin mRNA was removed from the total RNA using the globin reduction method according to the manufacturer’s recommended protocol (Affymetrix, Santa Clara, CA)."	"Biotinylated cRNA were prepared according to the standard Affymetrix protocol from 2 ug total RNA (GeneChip® Expression Analysis Technical Manual, 2001, Affymetrix)."	"Following fragmentation, 10 ug of cRNA were hybridized for 16 hr at 45C on GeneChip Human Genome U133 Plus 2.0 Array in Hybridization Oven 640 (Affymetrix). GeneChips were washed and stained in the Affymetrix Fluidics Station 450 using GeneChip Hybridization, Wash and Stain Kit (Affymetrix)."	"GeneChips were scanned using the GeneChip Scanner 3000, 7G (Affymetrix)."	"The expression analysis file created from each chip (sample) was imported into GeneSpring GX version 7.3 software (Agilent Technologies, Santa Clara, CA) for further data characterization. Each array was normalized (mean centered) to the median intensity array."	"ID_REF = <br>VALUE = GCOS version1.4 signal intensity"
Study Protocol URI	""	""	""	""	""	""	""	""
Study Protocol Version	""	""	""	""	""	""	""	""
Study Protocol Parameters Name	""	""	""	""	""	""	""	""
Study Protocol Parameters Name Term Accession Number	""	""	""	""	""	""	""	""
Study Protocol Parameters Name Term Source REF	""	""	""	""	""	""	""	""
Study Protocol Components Name	""	""	""	""	""	""	""	""
Study Protocol Components Type	""	""	""	""	""	""	""	""
Study Protocol Components Type Term Accession Number	""	""	""	""	""	""	""	""
Study Protocol Components Type Term Source REF	""	""	""	""	""	""	""	""
STUDY CONTACTS
Study Person Last Name	"Sato"	"Minoura"	"Akiyama"	"Nakahata"	"Nomoto"	"Ogihara"	"Ogata"	"Ishii"	"Kokubo"	"Kobayashi"
Study Person First Name	"Kayoko"	"Kastunori"	"Kazumasa"	"Yayoi"	"Keiko"	"Yoshihito"	"Shohei"	"Masahiro"	"Kenichi"	"Hirosuke"
Study Person Mid Initials	""	""	""	""	""	""	""	""	""	""
Study Person Email	""	""	""	""	""	""	"ogata_med115@yahoo.co.jp"	""	""	""
Study Person Phone	""	""	""	""	""	""	"81-42-778-8441"	""	""	""
Study Person Fax	""	""	""	""	""	""	"81-42-778-8829"	""	""	""
Study Person Address	""	""	""	""	""	""	"Pediatrics, Kitasato University, School of Medicine, 1-15-1, Kitasato, Sagamihara, Kanagawa, Japan"	""	""	""
Study Person Affiliation	""	""	""	""	""	""	"Kitasato University, School of Medicine"	""	""	""
Study Person Roles	""	""	""	""	""	""	"submitter"	""	""	""
Study Person Roles Term Accession Number	""	""	""	""	""	""	""	""	""	""
Study Person Roles Term Source REF	""	""	""	""	""	""	""	""	""	""
Comment[Study Person REF]	""	""	""	""	""	""	""	""	""	""